While Daybue sales and Acadia performance has a bearing on the current SP it certainly is a byplay to the ultimate destination of Neuren as a company. We should be focused on the upcoming trial results and an announcement regarding which candidate will be selected to move into the next trial and ultimately FDA approval; however I believe we’ll be well and truly sold by then, in JP we trust.
Acadia, page-740
-
- There are more pages in this discussion • 106 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.61 |
Change
0.280(2.10%) |
Mkt cap ! $1.739B | |||
| Open | High | Low | Value | Volume |
| $13.49 | $13.64 | $13.30 | $4.821M | 356.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 3602 | $13.55 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.66 | 1655 | 2 |
View Market Depth
| Last trade - 16.10pm 12/09/2024 (20 minute delay) ? |
| NEU (ASX) Chart |